A Phase 1b/2a Study to Evaluate the Efficacy of BX003 in Reducing the Intestinal Bacterial Burden of Klebsiella Pneumoniae in Target Bacteria Carriers
Latest Information Update: 24 May 2021
At a glance
- Drugs BX 003 (Primary)
- Indications Klebsiella infections
- Focus Therapeutic Use
- Sponsors BiomX
- 18 May 2021 According to a BiomX media release, results expected by the second quarter of 2022.
- 02 Feb 2021 According to a BiomX media release, Phase 1b/2 trial of BX003 for the reduction of K. pneumonia will start based on data from this trial.
- 26 Nov 2020 New trial record